Although there is still doubt about the effectiveness of gastric cancer drugs, several molecules such as bemarituzumab, which targets proto-oncogene c-SRC (src), tyrosine-protein kinase (ptk), and Mastinib, which targets fibroblast growth factor 2 (fgf2), may be the potential drugs under investigation in clinical trials17. This evidence concerns the gene SRC and gastric cancer.